Literature DB >> 7571414

The growth advantage conferred by HIV-1 nef is determined at the level of viral DNA formation and is independent of CD4 downregulation.

M Y Chowers1, M W Pandori, C A Spina, D D Richman, J C Guatelli.   

Abstract

Recent data on the phenotype of nef-defective HIV-1 in vitro indicate a new function of the Nef gene product: enhancement of viral infectivity. Single-cycle replication studies have suggested that Nef enhances the efficiency of an early step during viral replication, a step that leads to the establishment of viral DNA. To test this interpretation, the accumulation of low-molecular-weight (unintegrated) viral DNA was measured in cells following exposure to wild-type and nef-defective viruses. nef-defective virus accumulated less DNA than the wild type. This difference was observed after as little as 5 hr of exposure to virus. However, the reverse transcriptase activities of wild-type and nef-defective viruses were equal when measured in cell-free assays using either exogenous or endogenous templates. In addition, the abilities of these viruses to bind and enter cells were not significantly different. Together, these data suggest that Nef optimizes postentry events that are required for efficient synthesis of viral DNA. To determine if these effects were related to the property of Nef-mediated downregulation of CD4, growth curves of these viruses were determined using cells that express a CD4 molecule unable to respond to Nef. nef-defective virus remained attenuated in these cells, indicating that Nef-mediated downregulation of CD4 is not required for Nef-mediated enhancement of viral propagation in vitro.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7571414     DOI: 10.1006/viro.1995.1502

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  64 in total

1.  Human immunodeficiency virus type 1 particles pseudotyped with envelope proteins that fuse at low pH no longer require Nef for optimal infectivity.

Authors:  N Chazal; G Singer; C Aiken; M L Hammarskjöld; D Rekosh
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

2.  Human immunodeficiency virus type 1 Nef functions at the level of virus entry by enhancing cytoplasmic delivery of virions.

Authors:  E Schaeffer; R Geleziunas; W C Greene
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

3.  Pseudotyping human immunodeficiency virus type 1 (HIV-1) by the glycoprotein of vesicular stomatitis virus targets HIV-1 entry to an endocytic pathway and suppresses both the requirement for Nef and the sensitivity to cyclosporin A.

Authors:  C Aiken
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

4.  Nef enhances human immunodeficiency virus type 1 infectivity in the absence of matrix.

Authors:  Tatyana Dorfman; Elena Popova; Massimo Pizzato; Heinrich G Göttlinger
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

5.  The HIV-1 Nef protein enhances the affinity of reverse transcriptase for RNA in vitro.

Authors:  Cécile Fournier; Jean-Claude Cortay; Caroline Carbonnelle; Chantal Ehresmann; Roland Marquet; Pierre Boulanger
Journal:  Virus Genes       Date:  2002-12       Impact factor: 2.332

6.  cis expression of the F12 human immunodeficiency virus (HIV) Nef allele transforms the highly productive NL4-3 HIV type 1 to a replication-defective strain: involvement of both Env gp41 and CD4 intracytoplasmic tails.

Authors:  E Olivetta; K Pugliese; R Bona; P D'Aloja; F Ferrantelli; A C Santarcangelo; G Mattia; P Verani; M Federico
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

7.  Comparative proteomic analysis of HIV-1 particles reveals a role for Ezrin and EHD4 in the Nef-dependent increase of virus infectivity.

Authors:  Christelle Brégnard; Alessia Zamborlini; Marjorie Leduc; Philippe Chafey; Luc Camoin; Ali Saïb; Serge Benichou; Olivier Danos; Stéphane Basmaciogullari
Journal:  J Virol       Date:  2013-01-16       Impact factor: 5.103

8.  Nef does not affect the efficiency of human immunodeficiency virus type 1 fusion with target cells.

Authors:  Minoru Tobiume; Janet E Lineberger; Christopher A Lundquist; Michael D Miller; Christopher Aiken
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

9.  Inefficient human immunodeficiency virus replication in mobile lymphocytes.

Authors:  Marion Sourisseau; Nathalie Sol-Foulon; Françoise Porrot; Fabien Blanchet; Olivier Schwartz
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

10.  A naturally occurring variation in the proline-rich region does not attenuate human immunodeficiency virus type 1 nef function.

Authors:  Elke Rücker; Jan Münch; Steffen Wildum; Matthias Brenner; Jutta Eisemann; Leonid Margolis; Frank Kirchhoff
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.